There May Be Underlying Issues With The Quality Of Windlas Biotech's (NSE:WINDLAS) Earnings
Nov 20
Have your own idea? Try our Stock Screener
Indian (NIFTY) Life Sciences Industry Analysis
UpdatedDec 02, 2024
DataAggregated Company Financials
Companies17
- 7D3.9%
- 3M16.5%
- 1Y53.9%
- YTD46.1%
In the last week, the Life Sciences industry is up 3.9%, with Divi's Laboratories up 2.9%. Meanwhile, Akums Drugs and Pharmaceuticals actually underperformed within the industry, shrinking 5.5% in the last week. In the last 12 months, the industry was up 54%. As for the next few years, earnings are expected to grow by 23% per annum.
Industry Valuation and Performance
Has the Indian Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 02 Dec 2024 | ₹2.5t | ₹254.2b | ₹28.8b | 49.4x | 86.3x | 9.8x |
| Wed, 30 Oct 2024 | ₹2.3t | ₹247.9b | ₹26.4b | 49.6x | 89.2x | 9.5x |
| Fri, 27 Sep 2024 | ₹2.3t | ₹247.6b | ₹26.3b | 49.1x | 85.7x | 9.1x |
| Sun, 25 Aug 2024 | ₹2.1t | ₹247.1b | ₹23.8b | 38.2x | 87.9x | 8.5x |
| Tue, 23 Jul 2024 | ₹1.8t | ₹201.9b | ₹23.9b | 37.6x | 74.9x | 8.9x |
| Thu, 20 Jun 2024 | ₹1.7t | ₹194.5b | ₹21.5b | 33.9x | 80.6x | 8.9x |
| Sat, 18 May 2024 | ₹1.6t | ₹193.9b | ₹21.6b | 34.7x | 73x | 8.1x |
| Mon, 15 Apr 2024 | ₹1.4t | ₹168.5b | ₹18.6b | 29.5x | 77.5x | 8.6x |
| Wed, 13 Mar 2024 | ₹1.4t | ₹168.5b | ₹18.6b | 30x | 73.2x | 8.1x |
| Fri, 09 Feb 2024 | ₹1.4t | ₹166.6b | ₹19.0b | 33.2x | 74.5x | 8.5x |
| Sun, 07 Jan 2024 | ₹1.5t | ₹155.9b | ₹18.1b | 23.8x | 80.8x | 9.4x |
| Tue, 05 Dec 2023 | ₹1.4t | ₹155.9b | ₹18.1b | 22.4x | 77.3x | 9x |
| Thu, 02 Nov 2023 | ₹1.2t | ₹156.0b | ₹19.8b | 23.5x | 63.1x | 8x |
| Sat, 30 Sep 2023 | ₹1.4t | ₹154.7b | ₹19.7b | 26.4x | 71.8x | 9.1x |
| Mon, 28 Aug 2023 | ₹1.4t | ₹154.7b | ₹19.7b | 27.6x | 69.2x | 8.8x |
| Wed, 26 Jul 2023 | ₹1.4t | ₹156.5b | ₹23.0b | 30.1x | 60.2x | 8.9x |
| Fri, 23 Jun 2023 | ₹1.3t | ₹157.2b | ₹23.0b | 28.8x | 57.2x | 8.4x |
| Sun, 21 May 2023 | ₹1.2t | ₹160.8b | ₹22.9b | 32.9x | 51.6x | 7.3x |
| Tue, 18 Apr 2023 | ₹1.2t | ₹159.5b | ₹28.4b | 33.4x | 40.9x | 7.3x |
| Thu, 16 Mar 2023 | ₹1.0t | ₹159.5b | ₹28.4b | 30.7x | 36.9x | 6.6x |
| Sat, 11 Feb 2023 | ₹1.1t | ₹158.9b | ₹28.3b | 34.2x | 37.2x | 6.6x |
| Mon, 09 Jan 2023 | ₹1.2t | ₹164.9b | ₹34.5b | 30.5x | 35.8x | 7.5x |
| Wed, 07 Dec 2022 | ₹1.2t | ₹164.9b | ₹34.5b | 34x | 35.3x | 7.4x |
| Fri, 04 Nov 2022 | ₹1.3t | ₹164.1b | ₹36.1b | 37.5x | 37.3x | 8.2x |
| Sun, 02 Oct 2022 | ₹1.3t | ₹162.5b | ₹35.7b | 36.2x | 36.2x | 8x |
| Tue, 30 Aug 2022 | ₹1.3t | ₹162.6b | ₹35.8b | 37x | 35.8x | 7.9x |
| Thu, 28 Jul 2022 | ₹1.3t | ₹159.0b | ₹34.4b | 34x | 38.4x | 8.3x |
| Sat, 25 Jun 2022 | ₹1.3t | ₹158.3b | ₹34.2b | 33x | 37.6x | 8.1x |
| Mon, 23 May 2022 | ₹1.4t | ₹149.9b | ₹30.3b | 34.9x | 47.9x | 9.7x |
| Wed, 20 Apr 2022 | ₹1.5t | ₹148.3b | ₹29.4b | 37.3x | 51.7x | 10.2x |
| Fri, 18 Mar 2022 | ₹1.5t | ₹148.3b | ₹29.4b | 35.5x | 52.3x | 10.4x |
| Sun, 13 Feb 2022 | ₹1.5t | ₹139.8b | ₹25.1b | 37.6x | 59.1x | 10.6x |
| Tue, 11 Jan 2022 | ₹1.6t | ₹137.8b | ₹24.6b | 35.9x | 63.1x | 11.3x |
| Thu, 09 Dec 2021 | ₹1.6t | ₹137.8b | ₹24.6b | 31.6x | 64.1x | 11.4x |
Price to Earnings Ratio
64.1x
Current Industry PE
- Investors are optimistic on the Indian Life Sciences industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 86.3x which is higher than its 3-year average PE of 58.9x.
- The 3-year average PS ratio of 8.6x is lower than the industry's current PS ratio of 9.8x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have grown 5.4% per year over the last three years.
- Revenues for these companies have grown 23% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Indian Healthcare industry?
| IN Market | 2.94% | |
| Healthcare | 1.91% | |
| Life Sciences | 3.87% | |
| Clinical Research and Equipment | 3.87% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| DIVISLAB Divi's Laboratories | ₹6.17k | 2.9% +₹46.3b | 62.8% | PE89.3x | |
| SYNGENE Syngene International | ₹940.80 | 8.2% +₹28.7b | 26.0% | PE78.3x | |
| INDGN Indegene | ₹682.25 | 6.6% +₹10.0b | n/a | PE43.8x | |
| 524394 Vimta Labs | ₹903.10 | 18.7% +₹3.2b | 116.9% | PE40.7x | |
| WINDLAS Windlas Biotech | ₹1.09k | 13.7% +₹2.7b | 158.1% | PE37.3x |